Journal
CANCER REPORTS
Volume 5, Issue 10, Pages -Publisher
WILEY
DOI: 10.1002/cnr2.1654
Keywords
cancer care; cancer management; cancer medicine; clinical observations; head and neck cancer; immunotherapy
Categories
Funding
- Ayala
- Eisai
- Genentech
- Merck
- Pfizer
Ask authors/readers for more resources
This article reports a case of unresectable or metastatic differentiated thyroid carcinoma treated with lenvatinib and external beam radiation therapy. The patient showed clinical, biochemical, and radiological response after 5 months of lenvatinib and subsequently received external beam radiation. 21 months post-initiation of treatment, the patient enjoys good quality of life without evidence of cancer progression.
Background: Patients with unresectable or metastatic differentiated thyroid carcinoma (DTC) are rare and require individualized therapy. This may require approaches not typically used in resectable disease. We report a patient treated with lenvatinib and external beam radiation therapy. Case: An 87-year-old woman presented with cT4N1aM1 papillary thyroid carcinoma with tracheal invasion. She was not a candidate for surgery, radioactive-iodine, or radiation, so a trial of lenvatinib was offered. Her tumor showed clinical, biochemical, and radiological response after 5 months of lenvatinib, and she subsequently received external beam radiation. She enjoys good quality of life without evidence of cancer progression off therapy 21 months post-initiation of treatment. Conclusion: Lenvatinib may be effective in RAI-naive advanced DTC patients as a component of individualized multimodal therapy when conventional options are not feasible.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available